key: cord-0893879-p4je42i9
authors: Regula, Prudhvi; Rosenstreich, David; Jerschow, Elina; Ramesh, Manish; Ferastraoaru, Denisa; Oh, Jessica; Aivazi, Daniella S.; Aivazi, Jonathan M.; Hudes, Golda
title: Safety and Efficacy of Graded Dosing of Pfizer-BioNTech mRNA COVID-19 Vaccine after an Immediate Hypersensitivity Reaction to First Dose
date: 2022-04-30
journal: Journal of Allergy and Clinical Immunology: Global
DOI: 10.1016/j.jacig.2022.04.005
sha: f82119082373f30a10223701697981bbf4b9efd1
doc_id: 893879
cord_uid: p4je42i9

nan

Immediate Hypersensitivity Reaction to First Dose 2 3 4

Authors: 5 6

Prudhvi Regula, MD 1 7

David Rosenstreich, MD 1 8

Elina Jerschow, MD, MSc 1 9

Manish Ramesh, MD, PhD 1 10

Denisa (2), while initial reports of mRNA COVID-19 vaccination estimated the 48 incidence of anaphylaxis to be 2.5 to 4.7 cases per million doses(3). This higher anaphylaxis rate 49 compared to the risk associated with other vaccine (3), has led to a significant amount of vaccine 50 hesitancy(4). Current CDC guidelines recommend that individuals who have experienced a 51 severe reaction to the first dose are contraindicated from receiving further doses(5). Documented 52 pre-existing hypersensitivity to excipients, such as polyethylene glycol (PEG) or polysorbate 80 53 (PS80), are also contraindications(5) although recent studies have shown that the role of 54 excipient skin testing in determining PEG allergy is limited(6). There are no clear guidelines on 55 how to proceed with the management of these patients. 56

A CDC working group has speculated that patients with an adverse allergic reaction to the first 57 dose of mRNA COVID-19 vaccines could consider a subsequent dose of the Janssen adenovirus-58 based vaccine, but the safety and efficacy of a mixed series have not been adequately studied (7) 59 and the thrombosis risk of the Janssen vaccine is an additional concern. For patients who develop 60 anaphylaxis after receiving a non-COVID-19 vaccine and need subsequent vaccine doses, 61 current guidelines recommend graded vaccine administration for those with a positive vaccine 62 skin test(8). However, because mRNA is unstable, there is some concern about the effectiveness 63 of graded administration of this type of vaccine. Currently, data on the immunogenicity of 64 hypersensitivity reaction to a first dose of mRNA COVID19 vaccine is limited to one case series 66 of 15 patients reported by Tuong et al(9) . This group demonstrated the efficacy of graded dosing 67 by comparing post-graded dosing spike antibody levels with antibody levels in healthy subjects 68 who received both doses of an mRNA COVID-19 vaccine. 69

We report our experience with graded dosing to a second dose of Pfizer vaccine in patients who 70 experienced an immediate hypersensitivity reaction (within 4 hours) to a first dose of any mRNA 71 COVID-19 vaccine. Ten patients seen at our allergy clinic who met these criteria were identified 72 by retrospective chart review. We compared pre-and post-graded dose administration COVID-73 19 spike antibody levels after vaccine graded dosing. Details of the characteristics of all the 74 patients are described in Table I . Patients were predominantly female (90%), of diverse racial 75 backgrounds and the mean age was 42 years. The majority had at least one allergic comorbidity 76 (80%). Two patients (20%) had a history of an allergic reaction to influenza vaccine. Pfizer-77

BioNTech mRNA COVID-19 vaccine was the first dose vaccine in the majority (70%) of 78 patients. Six patients (60%) had developed anaphylaxis (based on WAO anaphylaxis criteria, 79 2020), and four had required epinephrine treatment. Since Moderna mRNA COVID-19 vaccine 80

was not available at our center, all these patients, regardless of their first dose vaccine, received 81

Pfizer mRNA COVID-19 vaccine in incremental doses at 30-minute intervals to a cumulative 82 dose of 0.3mL (Table II) . The protocol used for graded dosing varied based on physician 83 judgement. All patients were premedicated with a second-generation H1 antihistamine on the 84 day of vaccination and all patients were observed for one hour after the final vaccine dose. 85

Covid-19 spike antibody levels were measured at least two weeks after the procedure. 86

Only one patient (10%) developed mild symptoms during graded dosing (Table II) In our case series, only two patients had excipient skin testing with medications containing PEG, 99 while the rest underwent graded dosing without excipient testing. All patients in our series 100 tolerated the procedure regardless of testing, suggesting that graded vaccine administration 101 without excipient testing is safe. 102

Since two (or more) doses of these mRNA vaccines are crucial for protection against the SARS-103

CoV-2 virus, graded dosing is imperative for those experiencing immediate hypersensitivity 104 reactions. Customizing the graded dose protocol based on the severity of the prior reaction did 105 not change the outcome. The same protocol can be also used for administrating booster doses for 106 these patients. This vaccine graded dosing regimen should be an effective tool for promoting 107 complete vaccination, booster doses and mitigating vaccine hesitancy in patients who had 108 developed an immediate allergic reaction to the first dose. 109

To our knowledge, this is the first case series to report the safety of graded dosing of COVID-19 110 mRNA vaccine by using a customized protocol for each patient and also for demonstrating the 111 

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19

Among Hospitalized Adults Aged ≥65 Years -United States

J o u r n a l P r e -p r o o f 2.McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. 125 Risk of anaphylaxis after vaccination in children and adults. Journal